|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
774467126 |
| 003 |
DE-627 |
| 005 |
20230426191548.0 |
| 007 |
tu |
| 008 |
131212s2013 gw ||||| 00| ||ger c |
| 035 |
|
|
|a (DE-627)774467126
|
| 035 |
|
|
|a (DE-599)BSZ397975090
|
| 035 |
|
|
|a (OCoLC)865096219
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a ger
|
| 044 |
|
|
|c XA-DE
|c XD-US
|
| 082 |
0 |
4 |
|a 610
|q DNB
|
| 084 |
|
|
|a YG 2603
|q BSZ
|2 rvk
|0 (DE-625)rvk/153484:12909
|
| 084 |
|
|
|a 44.90
|2 bkl
|
| 084 |
|
|
|a 44.38
|2 bkl
|
| 245 |
1 |
0 |
|a Alemtuzumab
|b humanisierter monoklonaler Antikörper in der MS-Therapie
|c [Hrsg. und Autor: Heinz Wiendl]
|
| 264 |
|
1 |
|a Stuttgart [u.a.]
|b Thieme
|c 2013
|
| 300 |
|
|
|a 15 S.
|b Ill., graph. Darst.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 490 |
1 |
|
|a Thieme drug report
|v 7.2013,17
|
| 700 |
1 |
|
|a Wiendl, Heinz
|e hrsg
|4 edt
|
| 830 |
|
0 |
|a Thieme drug report
|v 7.2013,17
|9 2013000717
|w (DE-627)547222505
|w (DE-576)275732320
|w (DE-600)2393126-7
|x 1865-2875
|7 ns
|
| 912 |
|
|
|a GBV_ILN_74
|
| 912 |
|
|
|a ISIL_DE-354
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 936 |
r |
v |
|a YG 2603
|b Kompendien, Repetitorien, Leitfäden, Kurzdarstellungen, programmierter Unterricht
|k Medizin
|k Neurologie
|k Allgemeine Neurologie
|k Allgemeine Therapie
|k Medikamentöse Therapie
|k A. Formalschlüssel
|k Kompendien, Repetitorien, Leitfäden, Kurzdarstellungen, programmierter Unterricht
|0 (DE-627)1277423083
|0 (DE-625)rvk/153484:12909
|0 (DE-576)207423083
|
| 936 |
b |
k |
|a 44.90
|j Neurologie
|0 (DE-627)106409980
|
| 936 |
b |
k |
|a 44.38
|j Pharmakologie
|0 (DE-627)106409743
|
| 951 |
|
|
|a BO
|
| 980 |
|
|
|2 74
|1 01
|x 0354
|b 1449928102
|c 00
|f Magazin
|d Z 5038-7,17
|e u
|j --%%--
|y zb
|z 12-12-13
|
| 982 |
|
|
|2 74
|1 00
|x DE-354
|8 00
|a Antibodies, Monoclonal, Humanized
|
| 982 |
|
|
|2 74
|1 00
|x DE-354
|8 01
|a Antineoplastic Agents-therapeutic use
|
| 982 |
|
|
|2 74
|1 00
|x DE-354
|8 02
|a Multiple Sclerosis-drug therapy
|
| 984 |
|
|
|2 74
|1 01
|x 0354
|a 354$13107445
|
| 985 |
|
|
|2 74
|1 01
|x 0354
|a Z 5038-7,17
|
